David Lawrence, MD
Nuclear Cardiology · Cherry Hill, NJNPI 1245219989
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,644 of the $3,164 with a category attached, or 83.6%. It is spread thinly across 19 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nuclear cardiology clinicians in NJ, where the typical reported total is $3,343.
Across 92 payments — averaging $34.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$680
- Boston Scientific$402
- E.r. Squibb & Sons, L.L.C.$339
- Johnson & Johnson$276
- Kestra Medical Technology Services, Inc.$216
- Amgen$204
- plus $1K from 13 others
What the payments were for
- Consulting fees$50016%
- Food & beverage$2,64484%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 2 | $680 |
| Boston Scientific | 7 | $402 |
| E.r. Squibb & Sons, L.L.C. | 19 | $339 |
| Johnson & Johnson | 10 | $276 |
| Kestra Medical Technology Services, Inc. | 4 | $216 |
| Amgen | 14 | $204 |
| Abbott | 2 | $187 |
| Sanofi-aventis U.S. LLC | 6 | $160 |
| Irhythm Technologies, Inc. | 2 | $143 |
| AstraZeneca | 3 | $140 |
| Novartis | 8 | $111 |
| Atricure, Inc. | 1 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $86 |
| Amarin Pharma, Inc. | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Bayer | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER SMART SYSTEM$680
- ENSITE$129
- ZIO XT Patch$127
- FARXIGA$116
- CAMZYOS$115
- ELIQUIS$113
- XARELTO$113
- WATCHMAN FLX$106
How this compares
$3,164 in reported general payments places this provider in the 45th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 614 | $813,381 |
| XareltoRivaroxaban | 228 | $271,049 |
| EntrestoSacubitril/Valsartan | 84 | $119,798 |
| Repatha SureclickEvolocumab | 116 | $100,542 |
| MultaqDronedarone Hcl | 21 | $45,289 |
| Praluent PenAlirocumab | 46 | $43,613 |
| BrilintaTicagrelor | 20 | $19,369 |
| Metoprolol Succinate | 975 | $15,698 |
| Icosapent Ethyl | 42 | $15,095 |
| WegovySemaglutide | 11 | $14,268 |
| CorlanorIvabradine Hcl | 15 | $11,141 |
| Atorvastatin Calcium | 787 | $9,125 |
| CrestorRosuvastatin Calcium | 11 | $8,832 |
| Rosuvastatin Calcium | 592 | $8,751 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $8,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $813,381614 claims |
| Johnson & JohnsonXarelto | $276 | $271,049228 claims |
| NovartisEntresto | $111 | $119,79884 claims |
| Sanofi-aventis U.S. LLCMultaq | $160 | $45,28921 claims |
| AstraZenecaBrilinta, Crestor | $140 | $28,20131 claims |
| AmgenCorlanor | $204 | $11,14115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Cherry Hill
- Mark FinchCherry Hill$28K
- Nasser ChaudhryCherry Hill$11K
- Nicole KelbonCherry Hill$7K
- Kristofer HillegasCherry Hill$4K
- Amee DhariaCherry Hill$3K
- Rozy DunhamCherry Hill$3K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Hafeza ShaikhWillingboro$16K
- Ralph RussoMoorestown$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.